BeOne Medicines (NASDAQ:ONC) Price Target Raised to $418.00

BeOne Medicines (NASDAQ:ONC) had its price target increased by equities research analysts at Truist Financial from $416.00 to $418.00 in a research report issued to clients and investors on Thursday,Benzinga reports. The firm currently has a “buy” rating on the stock. Truist Financial’s target price would indicate a potential upside of 27.87% from the stock’s current price.

Other research analysts have also recently issued reports about the stock. Zacks Research cut shares of BeOne Medicines from a “strong-buy” rating to a “hold” rating in a research note on Friday, July 3rd. Morgan Stanley reissued an “overweight” rating and issued a $395.00 price target on shares of BeOne Medicines in a report on Thursday, May 7th. Barclays increased their price objective on BeOne Medicines from $403.00 to $407.00 and gave the company an “overweight” rating in a research note on Thursday. Citizens Jmp boosted their target price on shares of BeOne Medicines from $396.00 to $405.00 and gave the company a “market outperform” rating in a research note on Thursday. Finally, Wells Fargo & Company began coverage on shares of BeOne Medicines in a research note on Monday, May 4th. They set an “overweight” rating and a $400.00 price target on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $395.92.

BeOne Medicines Price Performance

NASDAQ ONC traded down $0.63 during trading hours on Thursday, reaching $326.90. The company’s stock had a trading volume of 139,726 shares, compared to its average volume of 279,777. The stock has a market cap of $35.87 billion, a PE ratio of 73.00 and a beta of 0.49. BeOne Medicines has a fifty-two week low of $253.95 and a fifty-two week high of $385.22. The company’s 50-day moving average is $294.53 and its two-hundred day moving average is $308.67. The company has a debt-to-equity ratio of 0.20, a quick ratio of 3.27 and a current ratio of 3.64.

BeOne Medicines (NASDAQ:ONC) last announced its earnings results on Wednesday, August 5th. The company reported $2.05 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.40 by $0.65. BeOne Medicines had a net margin of 8.94% and a return on equity of 12.06%. The company had revenue of $1.71 billion during the quarter, compared to analysts’ expectations of $1.66 billion. Analysts forecast that BeOne Medicines will post 5.93 EPS for the current year.

Insider Buying and Selling at BeOne Medicines

In other news, CEO John Oyler sold 145,861 shares of the stock in a transaction dated Tuesday, July 14th. The shares were sold at an average price of $305.95, for a total transaction of $44,626,172.95. Following the transaction, the chief executive officer owned 8,122 shares of the company’s stock, valued at approximately $2,484,925.90. This trade represents a 94.73% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Xiaobin Wu sold 1,484 shares of the business’s stock in a transaction dated Monday, June 8th. The shares were sold at an average price of $269.37, for a total value of $399,745.08. Following the completion of the sale, the chief operating officer directly owned 40 shares of the company’s stock, valued at approximately $10,774.80. This represents a 97.38% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 345,561 shares of company stock worth $105,625,947 over the last ninety days. Corporate insiders own 6.19% of the company’s stock.

Institutional Trading of BeOne Medicines

Hedge funds have recently bought and sold shares of the stock. Mariner LLC boosted its holdings in shares of BeOne Medicines by 3.8% during the 4th quarter. Mariner LLC now owns 883 shares of the company’s stock valued at $269,000 after acquiring an additional 32 shares in the last quarter. Signaturefd LLC grew its holdings in shares of BeOne Medicines by 10.7% in the fourth quarter. Signaturefd LLC now owns 340 shares of the company’s stock valued at $103,000 after acquiring an additional 33 shares in the last quarter. Farther Finance Advisors LLC grew its position in BeOne Medicines by 21.8% during the fourth quarter. Farther Finance Advisors LLC now owns 218 shares of the company’s stock valued at $66,000 after buying an additional 39 shares during the period. CWM LLC increased its holdings in BeOne Medicines by 32.8% in the 4th quarter. CWM LLC now owns 158 shares of the company’s stock worth $48,000 after acquiring an additional 39 shares during the last quarter. Finally, Steadtrust LLC grew its position in shares of BeOne Medicines by 3.7% in the second quarter. Steadtrust LLC now owns 1,400 shares of the company’s stock valued at $399,000 after purchasing an additional 50 shares in the last quarter. 48.55% of the stock is owned by institutional investors.

Key Stories Impacting BeOne Medicines

Here are the key news stories impacting BeOne Medicines this week:

• Positive Sentiment: Q2 results exceeded expectations: BeOne reported earnings of $2.05 per share, well above the $1.40 consensus estimate, while revenue reached $1.71 billion versus expectations of $1.66 billion. Revenue reportedly surged 30% year over year, signaling strong commercial momentum. BeOne Medicines Q2 earnings report
• Positive Sentiment: 2026 outlook was raised: Management now expects fiscal-year revenue of $6.6 billion to $6.8 billion, above the $6.5 billion Wall Street forecast. The higher outlook suggests confidence in demand for BeOne’s marketed cancer treatments. BeOne raises 2026 outlook
• Positive Sentiment: Analysts raised targets: Guggenheim lifted its price target from $420 to $430 and assigned a Buy rating, while Citizens JMP raised its target from $396 to $405 and maintained a Market Outperform rating. The revisions reflect stronger earnings and growth expectations. Analyst price-target updates
• Positive Sentiment: Pipeline development advanced: BeOne’s liver-cancer bispecific received a UK Innovation Passport, potentially supporting faster regulatory engagement and development of the candidate. UK Innovation Passport announcement
• Neutral Sentiment: Insider sale was tax-related: CFO Aaron Rosenberg sold 1,157 shares valued at approximately $362,000 to cover tax withholding associated with vested equity awards. Because the transaction was not described as discretionary, it is a limited bearish signal. SEC insider transaction filing
• Neutral Sentiment: Valuation remains demanding: Despite improving fundamentals and a generally favorable analyst view, ONC trades at a relatively high earnings multiple, leaving the stock sensitive to any slowdown in growth or disappointing pipeline news.

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.